Abstract:Vascular complications, such as impaired vasodilation, are a major problem that obese individuals face. In obesity, epididymal white adipose tissue (eWAT) expands, undergoes phenotypic changes, and begins to secrete a variety of adipokines that can metabolically regulate other organs and tissues including the cardiovascular system. Human studies report high levels of asprosin, a newly discovered adipokine secreted by WAT, in obesity. In this study, we hypothesize that obesity increases asprosin expression in eWAT which correlates to vascular complications.Eight-week-old male C57BL/6 mice were randomized into two experimental groups. The control group (n=7) received a standard chow diet (5% fat, 48.7% carbohydrates [3.2% sucrose]) and the Western Diet (WD) group (n=11) received a WD (40% fat, 43% carbohydrates [34% sucrose]) for 39 weeks. Obesity was confirmed by increased body weight (45.39 ± 1.98 g vs. 29.21 ± 0.79 g controls, p< 0.05) and increased BMI (0.45 ± 0.12 kg/m 2 vs. 0.32 ± 0.01 kg/m 2 controls, p< 0.05). At terminal experiments, eWAT was collected for histological and biochemical analysis. As expected, obese mice exhibited a greater amount of eWAT in comparison to the control group (2.69 ± 0.14 mg/g vs. 0.58 ± 0.06 mg/g controls, p< 0.05). Histological analysis of eWAT stained with H&E revealed that obesity induced a significant increase in adipocyte's size (10543.47 ± 694.06 μm 2 vs.1726.64 ± 152.20 μm 2 controls, p< 0.05) and infiltration of inflammatory cells surrounding adipocytes. Strikingly, greater asprosin expression was detected in eWAT from WD group in comparison to the control group (1.3 fold of increase, p<0.005). To assess whether asprosin has vascular effects, mesenteric arteries from control C57BL/6 mice were acutely incubated with pharmacological concentration of asprosin followed by vascular studies assessed by wire myograph. Our preliminary results show that asprosin impairs endothelium-dependent vasodilation (Emax:72.95% ± 7.38 vs. 93.33% ± 1.33 controls, n=3).The novelty of our results show that asprosin has a negative effect in vascular function. Our findings imply that eWAT may be a tissue contributing to the high levels of asprosin in obese individuals, further suggesting asprosin as a culprit of obesity-associated vascular dysfunction in obese males. This is the full abstract presented at the American Physiology Summit 2023 meeting and is only available in HTML format. There are no additional versions or additional content available for this abstract. Physiology was not involved in the peer review process.

Oxygen-Dependent Aspects of Asprosin Action

Asprosin in health and disease, a new glucose sensor with central and peripheral metabolic effects

Asprosin: its function as a novel endocrine factor in metabolic-related diseases

Asprosin, a C-Terminal Cleavage Product of Fibrillin 1 Encoded by the FBN1 Gene, in Health and Disease

The role of Asprosin in patients with dilated cardiomyopathy

Adipose Tissue-Specific PPARγ Deficiency Increases Resistance to Oxidative Stress

Serum Asprosin Concentrations Are Increased and Associated with Insulin Resistance in Children with Obesity

OLFR734 Mediates Glucose Metabolism as a Receptor of Asprosin.

Review of Asprosin as new Biomarker for diagnosis different Diseases

Increased asprosin in epididymal adipose tissue as a potential contributor to impaired vascular function in obese mice.

Asprosin levels in patients with type 2 diabetes mellitus, metabolic syndrome and obesity: A systematic review and meta-analysis

The role of asprosin in regulating ovarian granulosa- and theca-cell steroidogenesis: a review with comparisons to other adipokines

Protein tyrosine phosphatase receptor δ serves as the orexigenic asprosin receptor

Asprosin inhibits macrophage lipid accumulation and reduces atherosclerotic burden by up-regulating ABCA1 and ABCG1 expression via the p38/Elk-1 pathway

The impaired response of circulating asprosin concentrations to glucose levels fluctuation may be one of the causes of type 2 diabetes – a narrative review

Plasma Asprosin Levels Are Associated with Glucose Metabolism, Lipid, and Sex Hormone Profiles in Females with Metabolic-Related Diseases

Asprosin contributes to pathogenesis of obesity by adipocyte mitophagy induction to inhibit white adipose browning in mice

Relation of the intense physical exercise and asprosin concentrations in type 2 diabetic rats

Asprosin aggravates atherosclerosis via regulating the phenotype transformation of vascular smooth muscle cells

Asprosin: the potential player in combined double diabetes and hypothyroidism

Effects of Exhaustive Exercise on Adiponectin and High-Molecular-Weight Oligomer Levels in Male Amateur Athletes